Breaking News

Ripple XRP Cryptocurrency News

Ripple (XRP), like most other cryptocurrencies is having a rough time in the market today, following up on the recent declines that we’ve seen throughout the entire crypto industry. So, what’s the deal? Why is it that XRP is taking a dive? What’s going on in the world of cryptos? What’s next? Today, we’ll do our best to answer those questions.





What’s XRP Trading At Right Now?

As mentioned above, Ripple is having a rough time in the market, as it has been for some time now. Unfortunately, following up on recent declines, XRP is trading at $1.01 per coin after a drastic dive of 23.40%.

What Is Causing The Drop In Ripple

If you look across the board at cryptocurrencies as a whole, you’ll see that XRP isn’t the only one that is taking a dive. In fact, most cryptos are having a hard time in the market at the moment. Nonetheless, there is one bit of news related only to Ripple that can explain some of the drop.




Shortly after the new year, there was a bit of a spat on Twitter between a New York Times reporter and Brad Garlinghouse, CEO of XRP. When this spat happened, it dropped the price of Ripple slightly. However, it wasn’t this that caused the bloodbath. Unfortunately, more bad news was to come, and the news affected the crypto space as a whole.

CoinMarketCap Unexpectedly Removes Some Cryptos

Shortly after the spat between the CEO at Ripple and the New York Times Reporter on Twitter, more news hit that caused pain for XRP and the crypto market as a whole. In the same week, CoinMarketCap unexpectedly removed data from South Korean exchanges from its averages.

This unexpected move led to fear that regulation was going to hit in various areas. Of course, this fear led to a drop in crypto prices across the board, ultimately triggering more selling of XRP and leading to further declines.

Ripple Feels Even More Pain

This week, even more bad news hit for XRP. Earlier this week, reports came out of both China and South Korea. According to these reports, both countries are thinking about further regulatory smackdowns on cryptocurrency mining and exchanges. Considering that these two regions are overwhelmingly important for Ripple, this only exacerbated the declines that we’ve seen on the cryptocurrency as of late.

Russia Delivers Yet Another Blow

Finally, as if the news enough wasn’t enough to cause fear, more concern is coming as a result of comments made through reports about Russia. According to various reports, Russia is considering imposing stricter regulations on the cryptocurrency sector as a whole. In fact, TASS, a Russian news service, reported that Russian President Vladimir Putin said that “regulation will definitely be required in the future,” when speaking to the cryptocurrency market.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on XRP. In particular, we’re interested in following the story surrounding regulation in China, North Korea, and Russia. Nonetheless, there is something positive to watch for. At the end of the day, the centralized nature that separates XRP from other cryptocurrencies could make regulation easier, making it a more stable option in cryptocurrency in the future. In fact, this is why various major banks around the world are backing Ripple. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









ASML Holding NV (ADR) ASML Stock News

ASML Holding NV (ADR) (NASDAQ: ASML) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The Dutch tool and equipment supplier for the semiconductor industry provided stronger-than-expected fourth quarter results. Today, we’ll talk about the results, what we’re seeing from ASML, and what we’ll be watching for ahead.





ASML Smashes Q4 Expectations

As mentioned above, ASML Holding is having an incredibly strong day in the market today after the company released stronger-than-expected earnings for the fourth quarter. In fact, the earnings were so strong that many are pointing to a “supercycle” in global chip demand. Here’s what we saw from the earnings report:




  • Earnings – In the release, ASML said that earnings for the fourth quarter came in at €644 million. That’s a massive 23% increase, and it dwarfs analyst expectations of €454 million.
  • Guidance – In the release, the company also gave some pretty strong guidance. In fact, the company said that in the first 3 months of the year, it is expecting to generate €2.2 billion and that margins would improve to as high as 48%.

In a statement, Peter Wennink, CEO at ASML, had the following to offer:

“These results reflect our technology leadership and the success of our comprehensive product portfolio as well as the strong growth fundamentals in our industry, which enable the continued innovation in personal electronics, artificial intelligence, cloud computing and mobility… For 2018 we expect continued solid growth of sales and profitability.”

What We’re Seeing From The Stock

One of the first things that we learn as investors is that the news move the market. In this particular case, the news proved to be overwhelmingly positive, leading to strong gains in the value of ASML Holdings. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (12:05), ASML is trading at $197.15 per share after a gain of $10.77 per share (5.78%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ASML. In particular, we’re interested in following the continued growth in chip sales, leading to growth in both revenue and earnings. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required









Lam Research Corporation LRCX Stock News

Lam Research Corporation (NASDAQ: LRCX) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company was the center of a key analyst upgrade. Today, we’ll talk about the upgrade, what we’re seeing from the stock, and what we’ll be watching for with regard to LRCX ahead.





LRCX Gains Big On Upgrade

As mentioned above, Lam Research is having an overwhelmingly positive day in the market after being the center of a key upgrade. Yesterday, Susquehanna International upgraded the stock.

The investment research firm raised the rating on LRCX from Neutral to Strong Positive. At the same time, the price target on the stock was raised by 25%, from $200 to $250.

The analyst that increased the rating on LRCX was Mehdi Hosseini. Ultimately, he remains positive with regard to the strength of memory spending. The analyst pointed to increasing memory spending driven by cloud computing, big data, mobile devices, and IoT as reasons to be excited about Lam Research. With memory spending accounting for about 60% of shipments at LRCX, the analyst expects that both revenue and earnings will grow in the near future.




In fact, Hosseini said that he expects LCRX revenue to grow by at least 5% in the period from 2017 to 2020. This, he says, will be coupled with operating leverage and buybacks, which could drive earnings upward by more than 10% in the same period.

What We’re Seeing From The Stock

As investors, one of the first things that we learn is that the news moves the market. In this particular case, news of an upgrade by a highly credible analyst is leading to excitement surrounding Lam Research Corporation. As a result, we’re seeing strong gains in the value of the stock. Currently (11:38), LRCX is trading at $201.40 per share after a gain of $11.01 per share (5.79%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on LRCX. In particular, we’re interested in following the continued growth in memory spending and watching as this improves the fundamentals surrounding the company. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 296
Oncnova Therapeutics ONTX Stock News

Onconova Therapeutics Inc (NASDAQ: ONTX) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company provided an update with regard to their work toward the clinical development of rigosertib. Today, we’ll talk about the update, what we’re seeing from ONTX, and what we’ll be watching for ahead.





ONTX Announces Clinical Update

As mentioned above, Onconova Therapeutics is having an incredibly strong start to the trading session this morning after announcing a clinical update. In a press release issued early this morning, ONTX announced that it is moving forward with its Phase 3 INSPIRE pivotal trial. This announcement comes after the interim analysis, which was recommended by the DMC.




In the release, ONTX announced that the DMC recommended the continuation of the trial with a one-time expansion in enrollment. The INSPIRE Phase 3 clinical trial is designed to study intravenously-administered rigosertib in patients with higher-risk myelodysplastic syndromes who have progressed on, failed to respond to, or relapsed after prior HMA therapy.

In the press release, Onconova Therapeutics said that it would be adding 135 patients to the original target of 225 patients. So, based upon the DMC’s recommendations, the trial will include 360 study participants. In a statement, Guillermo Garcia-Manero, M.D., Professor and Chief of the MDS Section at the MD Anderson Cancer Center and a lead investigator on the ONTX trial, had the following to say:

“Choices are very limited for higher risk MDS patients after failure of HMA therapy and no second-line therapy has ever been approved by the Health Authorities for these patients. These patients have a very short life-span and there is a tremendous unmet medical need. We remail highly supportive of Onconova’s efforts. After the interim analysis, continuation of the INSPIRE study is encouraging for patients.”

What We’re Seeing From The Stock

As investors, one of the first things that we learn is that the news moves the market. In this particular case, the news proved to be overwhelmingly positive. So, it’s no surprise to see that Onconova Therapeutics is making a run for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:05), ONTX is trading at $1.95 per share after a gain of $0.21 per share (11.89%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ONTX. In particular, we’re interested in following the story surrounding the INSPIRE trial and excited to see the results as this important treatment makes its way through development. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 262
Juno Therapeutics Inc JUNO Stock News

Juno Therapeutics Inc (NASDAQ: JUNO) is having an overwhelmingly strong start to the trading session this morning after news broke that the company could be acquired relatively soon. Today, we’ll talk about the potential acquisition, what we’re seeing from JUNO as a result, and what we’ll be watching for ahead.





JUNO Climbs On Potential Acquisition

As mentioned above, Juno Therapeutics is having an incredibly strong start to the trading session this morning after news broke after-hours yesterday. According to various reports, Celgene Corporation (NASDAQ: CELG) is in advanced talks with Juno Therapeutics with regard to the potential acquisition of the company.




A member of the CNA Finance team reached out to JUNO. Unfortunately, a representative of the company could only tell us that it did not comment on rumors or speculation. With that said and without confirmation, it’s important to treat this as a rumor.

The reality is that rumors are a common occurrence in the market. While this rumor surrounding JUNO and CELG seems to hold more validity than most, it’s important to remember that rumors are the most common form of market manipulation! So, if you’re going to make a move based on this news, please be sure to do so with caution.

What We’re Seeing From The Stock

As investors, one of the first things that we learn is that the news causes movement. While this particular news is being treated as a rumor, it is definitely causing excitement among investors. This can be seen by the strong growth in the value of the stock. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:42), JUNO is trading at $68.96 per share after a gain of $23.36 per share (51.24%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on JUNO. In particular, we’re interested in learning if the rumor surrounding a CELG acquisition holds any validity. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 316
AEterna Zentaris AEZS Stock News

AEterna Zentaris Inc. (USA) (NASDAQ: AEZS) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced an asset sale that has been made with Strongbridge Biopharma plc (SBBP). Today, we’ll talk about the asset sale, what we’re seeing from the stock, and what we’ll be watching for with regard to AEZS ahead.





AEZS Gains On Asset Sale

As mentioned above, AEterna Zentaris is having an overwhelmingly strong start to the trading session this morning, after announcing an asset sale. In a press release issued early this morning, the company announced the sale of assets to Strongbridge Biopharma.




In the release, AEZS announced that it has sold the United States and Canadian rights to MACRILENTM (macimorelin). The treatment is approved in the United States for patients with adult growth hormone deficiency, an ailment that affects about 60,000 adults in the United States and Canada.

Under the terms of the agreement, SBBP has agreed to make an upfront payment of $24 million to AEZS. Also, SBBP will pay tiered royalties in the mid-to-high teens as a percentage of net sales as well as milestone payments upon FDA approval of a pediatric indication and the achievement of predetermined sales levels. In a statement, Matthew Pauls, President and CEO at SBBP, had the following to offer about the agreement with AEZS:

“We are extremely proud to acquire the U.S. and Canadian rights to MACRILEN, the first and only oral drug approved in the U.S. to diagnose adult growth hormone deficiency, or AGHD. MACRILEN has Orphan Drug Designation in the U.S. and was developed to address important unmet needs in the diagnosis and appropriate treatment of adult growth hormone deficiency, a condition that we believe is too often under-recognized or misdiagnosed, in part because of the lack of accurate, convenient and safe diagnostic procedures… The acquisition of MACRILEN builds upon our rare endocrine disease franchise and establishes our commercial presence in the space, marking an important step forward for Strongbridge’s overall growth and evolution. Importantly, this transaction occurs prior to the potential regulatory approval and market introduction of RECORLEV™ (levoketoconazole), currently in Phase 3 for endogenous Cushing’s syndrome, a condition often treated by the same endocrinologists who diagnose and treat AGHD,”

What We’re Seeing From The Stock

As investors, one of the first things that we learn is that the news moves the market. Any time positive news is released by a publicly-traded company, we can expect to see gains in the stock that is representative of the company. That’s exactly what we’re seeing from AEZS today. Currently (10:11), AEZS is trading at $2.67 per share after a gain of $0.60 per share (28.99%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on AEZS. In particular, we’re interested in following this deal through the close. We’re also interested in following the company’s ongoing development with regard to its impressive pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 373
Aytu Bioscience Inc AYTU Stock News

Catching emerging biotech stocks at their low’s isn’t necessarily difficult, but it does take a willingness to look at the derivatives that make up the whole when analyzing the opportunity. Those that are following Aytu BioScience (NasdaqCM: AYTU) are well aware of the company’s impressive growth in new prescription rates from Natesto®, the company’s nasally administered treatment to target low testosterone levels (hypogonadism) in men. Now, combined with the recently reported Advisory Committee setback of Lipocine Inc.’s, (NASDAQ: LPCN) TLANDO® and privately held Clarus Therapeutics, Jatenzo®, investors may be additionally bonused to find the prospects for Natesto® to be heightened significantly in potentially becoming the treatment of choice for both physician and patient. Here’s why:

Bad News For Lipocine Inc.’s TLANDO®

TLANDO® was expected to be an effective alternative to currently available products like AndroGel®, Axiron®, and Fortesta®, each of which carries a substantially inadequate safety profile and have been mandated by the FDA to include the most severe Black Box warning to its label. Yes, all three get stuck with that severe warning. And, yes, the FDA still allows them to sell the product. Go figure.

Now, as the potential newest testosterone treatment, even if TLANDO® makes it past a highly unlikely approval process, the chances that the product will make meaningful market headway is unlikely. But, let’s be about 99% clear. The opportunity for TLANDO® to gain FDA approval resides at a line of slim to none, and even if TLANDO® gets approved by some act of FDA bumbling, it will be highly improbable that the product would gain favor in the eyes of prescribers. In the opinion of many, especially the malpractice attorneys, prescribers are already taking a substantial risk in providing the products above to patients, knowing the considerable safety risks and associated events involved with each product.

Now aware that two late-stage TRT alternatives have all but fallen to the wayside, and with AndroGel®, Axiron®, and Fortesta® having their own set of significant safety risks, the big three in TRT may start to see their market grip evaporate toward Natesto®.  From there, these major players can decide at what point they want to side with Natesto®, which may open a whole host of new options for AYTU management to consider. And, taking into account all the benefits and its best-in-class safety profile, Natesto® may likely become the belle of the TRT ball in relatively short order. After all, what Big Pharma can’t beat, they buy.

The news that LPCN provided to the market last week was terrible. On January 10th Lipocine Inc. announced that the Bone, Reproductive and Urologic Drugs Advisory Committee (“BRUDAC”) of the U.S. Food and Drug Administration (“FDA”) voted six in favor and thirteen against the benefit/risk profile of TLANDO®, the company’s oral product for testosterone replacement therapy in adults with hypogonadism. Notably, the role of BRUDAC is to provide recommendations to the FDA about whether or not a drug should get approved for market. And although the recommendations of BRUDAC are non-binding and the FDA makes the final decision, it is very uncommon for the FDA to approve products that the Advisory Committee does not recommend for approval. In fact, it is improbable, except for the most urgent of humanitarian need that the FDA does not follow the recommendation by an Advisory Committee.

And, although the negative sentiment for TLANDO® provided juice to Natesto®, AYTU received even more good news on the competitive TRT front.

Similar Bad News For Jatenzo®

Also early last week, the FDA held an Advisory Committee meeting to review privately-held Clarus Therapeutics’s oral testosterone candidate Jatenzo®. Sharing the similar fate, Jatenzo® was rebuked by the advisory Committee primarily over safety concerns and similarly sent a recommendation that the product not be approved for market.

Two issues stood out as the basis for not recommending either product. Both are serious. The first matter cited as a reason for the adverse Advisory Committee sentiment on both of these oral testosterone therapies is the cardiovascular risk.  The second reason cited increasing hematocrit in the broader as a safety concern in the testosterone replacement category.

No need to explain cardiovascular risk. If your heart stops, it’s bad. But, the increase in the hematocrit levels is also a severe event, causing thicker blood within the user’s body, and is clinically shown to enhance the risk of stroke significantly. Although patients can try to compensate for the higher risk of stroke by reducing their TRT dosage or even quitting the therapy altogether, others turn to donating blood more frequently to thin it out. But, when push comes to shove, why should patients subject themselves to such extreme measures, especially when FDA-approved Natesto® is available as an alternative that is shown not to affect hematocrit levels, even after 360 days of continuous treatment? The quick answer is that they shouldn’t.

Natesto® Will Finally Get The Full Attention It Deserves

While AYTU may not openly rejoice in the apparent failure of both TLANDO® and Jatenzo®, the news is a shot-in-the-arm for AYTU and its lead product Natesto®, which is already FDA approved and has several clear advantages over other testosterone therapies. And, to be sure, Clarus and Lipocine’s seemingly failed attempts to enter the US market won’t interfere with AYTU’s ability to showcase Natesto® as the most advanced entrant in the enormous $2BN prescription testosterone market.  In fact, the case for Natesto® is made even stronger.

Despite not benefiting from the Big Pharma’s massive marketing budgets, Natesto® is beginning to gain significant market traction based on the company’s most recent updates. The company’s latest presentation reports a 250% total prescription growth rate for the three months ending in November compared to the three months ending in February of 2017. Additionally, factory sales were reported as all-time highs as of December at an annual run-rate of almost $7 million and had increased 300% over the last four quarters.

For both AYTU and Natesto®, this momentum may be just the beginning of a stronger trend higher, considering that the US market for testosterone replacement therapies is more than $2 billion. And, as noted, Natesto® is the only topical product without a black box warning – the strictest of warnings that all other topical testosterone’s carry due to the risk of potential transference.  Additionally, Natesto® is a lot easier to apply than testosterone gels and without any of the safety concerns that caused Lipocine and Clarus to get all but formally rejected by the FDA at last week’s Advisory Committees.  

Natesto® Should Be The Market Leader

It’s sometimes difficult to understand why the FDA even permits products to remain on the market when safe alternatives are available. But, they do, and Natesto® may provide a call to action for change.

Competing products being prescribed by physicians include AndroGel®, Axiron®, and Fortesta®, and each carries the severe Black Box warning in its label. And, they should. All three bring a substantial risk of accidental transference of the topically applied testosterone to both women and children if they are nearby during the application process. Results can be severe, and noticeable unwanted effects from only a brief exposure have been reported from minimal accidental transference. For the users of Black Box products, the adverse events can be more severe with cases citing cases of testicular shrinkage, lowering of LH and FSH hormone levels and a sharp reduction in sperm count.

Thankfully, recent AYTU product updates indicate that physicians are placing more focus on the safe, well tolerated, and best-in-class performance of Natesto®, and it is becoming apparent that Natesto® is beginning to gain increasing attention from prescribing physicians. Notably, the word is spreading that by weighing the known benefits of Natesto® against the risk-enhanced results shown from every other marketed low-T product available on the market that Natesto is a better option for treatment. Most important, prescribing physicians are getting educated to the fact that Natesto® does not cause many of those unwanted or adverse events associated with products they may currently provide.

You probably already know, but if not, Natesto® is AYTU’s FDA-approved and clinically proven therapy prescribed to treat hypogonadism, also known as low testosterone. Different from both injectable and topically applied TRT treatments, Natesto® is the only nasally delivered low-T therapy on the market. The gel application gets administered similarly to that of nasal allergy sprays, which offers the patient quick, measured, and convenient dosing. Regarding efficacy, clinical trials showed that sexual function and overall mood of male patients using Natesto® had improved significantly in as little as 30 days, and after 90 days of Natesto® use, about 90% of the patients had returned to normal testosterone levels. From a clinical perspective, the results indicate that Natesto® can potentially return low-T patients to baseline in roughly three months, and it can do so with fewer health risks than competing treatments in the market space.

Ironically, Natesto® is the only topical treatment not required to have a Black Box warning pinned to the product but is still fighting for market share. However, the product is gaining ground demonstrated by the month-over-month growth rate in new prescriptions written.

The Market Is Telling The Story

Although many in the industry find that the valuation of AYTU significantly underappreciates the potential and current growth trajectory of Natesto®, others appear to be taking advantage of the present low share price. Contrary to LPCN’s 50% plunge in share price last week, AYTU saw significant interest in its shares and on Friday closed out the week just over 20% higher on volume that exceeded 10X its recent average. On Tuesday, the interest in AYTU continued with shares closing higher by an additional 22% on extremely strong volume.

Rightfully, the sentiment is shifting, and many get the sense that Natesto® is on the verge of bringing an appropriate value to AYTU shares, thus playing a critical factor in driving shareholder value higher. AYTU share prices traded above $6 late last year and if anything, with the apparent failure of two of its competitor’s late-stage clinical stage products, the spike in stock price last week may be an indicator of things to come.

Perhaps the institutional investors that follow the multi-billion dollar TRT market finally realize that Natesto® may soon be the front man in the market after proving itself to be a best-in-class option for both its safety profile and treatment success rates. And, couple that reasoning with a yearly run-rate expected to eclipse $7 million that can ease cash concerns, then the 20% move last week may just be the beginning of something much bigger.

Disclaimer- CNA Finance is NOT an Investment Advisor. Our goal is to bring both news and under discovered stocks to the attention to investors to assist in making smart decisions in the market. CNA Finance is a for profit company. That profit is generated through three (3) different types of relationships. First and foremost, we work with pay per click and CPM advertisers on banners. We also have affiliate relationships with various companies where we earn a portion of the sales we refer. Finally, we may have relationships with some of the companies or IR firms that represent companies mentioned within our works in which we are compensated in cash and or stock for consulting, investor relations, and Press Release services. AYTU Bioscience pays CNA Finance $4,000 per month for research and writing services as well as other digital investor relations tasks. Therefore, while we do everything in our power to provide true, well-researched, and well-thought out opinions, in some instances, a potential conflict of interest may exist. CNA Finance encourages all investors to seek professional advice before making any investment decision.

FTE Networks FTNW Stock

As we enter the final two years of this technologically powered decade, it is more evident than ever that high-quality wireless connectivity and its accompanying infrastructure solutions are a competitive necessity for profit-minded and service-oriented companies. And, at the risk of sounding overly simplistic, a fast and reliable networking infrastructure can significantly augment a company’s productivity by allowing for quick transfers of data and seamless connectivity of company branches worldwide. Perhaps that’s why industry giants such as Google (NASDAQ: GOOGL) and ESPN, majority owned by Walt Disney Co. (NYSE: DIS), find it essential that the wireless connectivity and infrastructure provided to them is lightning fast, always functional, and tightly secured. Therein, enter FTE Networks, Inc. (NYSE: FTNW) – a company dedicated to providing state-of-the-art data-focused infrastructure to the businesses that need it most.

And, if the explosive increase in revenue and growing backlog of projects serves as an indication about the potential and demand for FTNW services, then consider them to be the emerging leader in a small and competitively constrained networking industry.

Innovative Platform Distinguishes FTNW

Founded in 2007, FTE Networks, Inc. is an emerging leader as a provider of innovative network connectivity infrastructure solutions to the IT and telecommunications industries. Reduced to simplest terms, FTNW provides latency reduced, end-to-end solutions that enable their clients to connect with their customers, utilizing cutting-edge technology to allow a fast and reliable connection for digital content. However, from a logistical perspective, the technology used and solutions provided are far from simple, making the field of able competitors to FTNW quite small.

With offices throughout the United States and Europe, FTNW has amassed valuable industry experience while building strong relationships with their customers, and as FTE’s name continues to gain recognition, the company has been able to expand their industry presence while improving product performance and streamlining costs. Taking advantage of their niche expertise, FTNW has cultivated strong business relationships with its clients through its unique ability to act as a “one-stop shop” for connectivity solutions, with a mission dedicated to build, manage, and maintain the infrastructure provided.

Additionally, unlike most of their competitors, the FTNW business model is designed to ensure the speedy delivery of a custom-tailored and durable solution to the client, facilitating reduced cost and increasing performance and efficiency standards. Through several accretive acquisitions, FTE Networks is uniquely positioned to provide an all-in-one solution for telecommunications, data and general contracting projects.

FTNW Provides Total Infrastructure Solutions

FTE Networks, Inc. is unique to the sector, taking advantage of their expansive portfolio of services that allow the company to target a significant number of high-value markets. Specifically, the company’s expertise centers around providing specialized service in the industries of commercial construction, data center buildout, network infrastructure and fiber installation, developing global smart-buildings, and in-building wireless technology. When combined, these five markets are estimated to offer a staggering $576 billion in potential revenues by 2021 – and by benefitting from the strategic acquisitions made by FTNW, the company is expecting to generate substantial revenue streams from each of these markets.

Broadening their scope of market opportunity, FTNW will take advantage of three company’s that now reside under the FTNW umbrella, with each providing a unique and valuable service. First and foremost is FTE Network Services, which offers end-to-end network infrastructure and telecommunications solutions to Tier 1 carriers, Fortune 1000 cable companies, and data-centric government agencies. FTE Network Services provides state-of-the-art fiber optic installation, which allows for best-in-class internet connectivity and speeds, along with the setup of data centers and company-wide wireless integration. The company also offers digital security and surveillance services, taking advantage of a growing demand which is becoming a necessity for businesses to protect the integrity of their IP and general operations. Before the acquisitions that set the combined FTNW into motion, FTE Network Services was already generating approximately $14 million in annual revenues, and this number is consistently increasing as FTE Networks continues to expand the company’s breadth of services.

CrossLayer Provides Long-Range Functionality

CrossLayer is a second company under the FTNW umbrella. CrossLayer is a single integrated communications platform, providing business owners with an ultra-fast and reliable network for their building or campus. The company is equipped with the latest in networking technology and works toward a primary goal to eliminate redundancy problems that exist within many of their more antiquated competitor’s networks. Whether it’s at home or work, most everyone has experienced the frustration of slow connection speeds or spotty service range – but at CrossLayer, providing seamless, latency-reduced connectivity is the number one priority. Knowing that today’s top businesses have no time for technical difficulties, CrossLayer has built their platform upon some of the most recent breakthroughs in networking technology, which allow for noticeably faster speeds at a much lower cost – astoundingly offering 1G of service for the same price as a typical 20MB connection.

Along with faster transmission speeds, the company works to ensure that their client’s network can get accessed by a multitude of customer devices from virtually anywhere in the building or campus. For those who attend or work on a college campus, for instance, experience shows that a campus-wide Wi-Fi solution can often struggle with reception and bandwidth issues. To address these limitations, CrossLayer’s DataGrid Campus Connect engages itself in providing the same secure and high-quality connection to anywhere on campus, facilitating a similar user experience as compared to more traditional hot-spot locations.

In addition to overcoming limitations from traditional connectivity placements, CrossLayer also enjoys the distinction of delivering exceptional service and installation for their clients in industry-leading fashion. Many of the company’s competitors can take up to ten weeks to finalize the setup of their network and are often just as slow to respond to service requests. CrossLayer, however, substantially reduces implementation time by working directly with the building owner through the entire process to quickly set up and manage their new network connection. Additionally, through the cooperative relationship, the company can efficiently set up industry-leading network infrastructure and ultimately provide the owner the ability to tailor their network to fit their specific needs.

Business and property owners that depend on an omnipresent network connection have much to gain from CrossLayer’s targeted services, and for those that are turning to FTNW to integrate those services will benefit from increased speed, functionality, and long-range connectivity advantages.

Benchmark Builders Provides The Foundation

The most recent addition to the FTE label is Benchmark Builders, Inc. Acquired by FTNW in April 2017, Benchmark Builders is a full-service general contracting company that designs and builds innovative and architecturally striking facilities. The company currently serves Fortune 1000, top-tier clients in the NYC Metro Area.

Expected to become a significant revenue generating asset, Benchmark Builders offers a full suite of services to meet the needs of their client, including construction management, general contracting, and pre-construction services. From corporate interiors to broadcast studios, Benchmark Builders is committed to delivering top quality results through each step of the construction process. The company is also dedicated to fully complying with OSHA safety regulations, which maximizes the safety of workers and contributes to reduced insurance costs for both BenchMark Builders and their clients. As an all-inclusive asset, Benchmark Builders has the resources, experience, and knowledge to ensure a successful construction process. More importantly, Benchmark will provide the opportunity for a fully customized and integrated communications framework that can allow the project owner to save millions of dollars, while at the same time benefitting from a well-designed and efficient data transmission infrastructure.

Setting Up To Crush 2018

With the combined services provided by FTE Network Services, CrossLayer, and Benchmark Builders, Inc., FTE Networks, Inc. is deserving of its reputation as a “one-stop shop” for construction and networking solutions. The company is positioned to maximize profitability through their ability to offer a complete host of networking, construction and maintenance solutions, which also results in a seamless and expedited process for their clients.

Entering the first quarter of 2018, FTNW has strategic plans to take full advantage of their three complementary businesses and is actively working toward obtaining patents to protect their technology and service offerings that differentiate themselves from their competitors. Also, by providing scalable and upgradeable solutions to their clients, the FTNW business model allows for long-term relationships that can generate sustainable growth and increase revenue opportunity.

Additionally, FTE already has the advantage of a strong market presence and reputation in the lucrative New York City market. This enviable position, coupled with the recent investments to expand the sales channels, will likely open numerous profitable opportunities for the company. And, by offering a better, faster, and less expensive service, FTNW is proving that their strategy works.

FTE Networks Looks Way Undervalued

FTE Networks generated roughly $177.9 million in revenues in 2017, and the company’s recent acquisitions will undoubtedly increase this number by significantly expanding the reach of services offered by FTNW. The company’s share price is sitting at $16.75 as of January 13, 2018, with 5.4 million shares outstanding and a market cap of only $70.5 million. Also important to note, the company has just recently been uplisted to the NYSE, which provides an immediate boost to their credibility and serves up an extensive list of institutional investors to diversify and broaden their shareholder base. These benefits, along with a recent deal with KCSA Strategic Communications for Public and Investor Relations, will leave FTE Networks fully equipped to attract a broader investment audience as they continue to take advantage of growth opportunities. The uplisting may already be proving its worth, likely prompting the share price increase of roughly 30% since the first week in January.

Overall, FTE Networks, Inc. has positioned themselves to take full advantage of a lucrative and expanding market. Through building a diverse portfolio on an already solid foundation, the company can provide total solutions to some of the most common and essential corporate telecom needs. Since inception, FTE has generated over $387 million in total revenues, and their unique and all-encompassing business model should work to keep their Fortune 1000 clients loyal to their services.

Investors should also keep in mind that the company’s intent to secure development and process patents on their technology distinguishes FTNW further and will strengthen the company’s ability to protect its enviable position and market-leading technology for years to come.

With FTNW trading at only $16.75 a share, and with a price to sales ratio far lower than industry peers, investors would be wise to consider the investment opportunity presented by FTNW. And, after accounting for the expected revenue generated from recent and accretive acquisitions, the record-breaking revenue growth and the lucrative backlog of projects, the case for investor attention and action is made that much greater.

Disclaimer- CNA Finance is NOT an Investment Advisor. Our goal is to bring both news and under discovered stocks to the attention to investors to assist in making smart decisions in the market. CNA Finance is a for profit company. That profit is generated through three (3) different types of relationships. First and foremost, we work with pay per click and CPM advertisers on banners. We also have affiliate relationships with various companies where we earn a portion of the sales we refer. Finally, we may have relationships with some of the companies or IR firms that represent companies mentioned within our works in which we are compensated in cash and or stock for consulting, investor relations, and Press Release services. Invictus Resources paid CNA Finance $3,000 for research and writing services as well as other digital investor relations tasks provided to FTE Networks. Therefore, while we do everything in our power to provide true, well-researched, and well-thought out opinions, in some instances, a potential conflict of interest may exist. CNA Finance encourages all investors to seek professional advice before making any investment decision.

Youngevity International YGYID Stock News

Youngevity International Inc (NASDAQ: YGYI) is having yet another in a string of strong days in the market today after announcing the opening of operations in Colombia. Today, we’ll talk about the news, why it’s such a positive for YGYI, what we’re seeing from the stock today, and what we’ll be watching for ahead.





YGYI Launches Operations In Colombia

As mentioned above, Youngevity International has had a string of strong trading sessions after recently announcing that it has opened operations in Colombia. In the press release, YGYI said that it has identified the company as one of the primary direct selling markets in Latin America. The expansion will be led by Country Manager, Angela Sierra under the supervision of Susana Azócar, Director of Sales and Operations for Latin America. In a statement, Luke Taffuri, VP of International Sales & Operations, had the following to offer:

“I’ve worked with Angela Sierra for the past 10 years, and I’m excited that her experience and skill set are available for this launch… The ability to acquire experienced and seasoned executives that can get up to speed quickly is a strong advantage of Youngevity’s acquisition strategy.”




Why This Is Such Big News

At the end of the day, opening operations in Colombia is great news for YGYI and its investors. After all, the company is setting up a 4,520 square foot headquarters in Bogotá, the capital of the nation that is considered to be a direct selling hub for Latin America. Ultimately, the opening of operations in the region will likely expand revenue and earnings in a big way, while creating strong economic opportunities for many in the region.

What We’re Seeing From YGYI

At the end of the day, investors continue to push the value of Youngevity International to the top as excitement builds surrounding the operations in Colombia. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (1:13), YGYI is trading at $5.42 per share after a gain of $0.16 per share or 3.13% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on YGYI. In particular, we’re interested in following the progress they make in Colombia and throughout Latin America. We’ll also be watching the continued and robust growth of CLR Roasters and others within the company’s impressive line of brands.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Helios and Matheson Analytics Inc HMNY Stock News

Helios and Matheson Analytics Inc (NASDAQ: HMNY) is having a rough day in the market today. However, with recent news surrounding the company being overwhelmingly positive, many are asking if now is the time to buy the dip. Today, we’ll talk about the recent news surrounding the stock, what we’re seeing from HMNY today, and what we’ll be watching for ahead.





HMNY Has Released Some Great News Recently

Recently, Helios and Matheson Analytics has received quite a bit of mainstream coverage, leading to the occasional spike in the value of the stock. About a month ago, we saw one of these spikes when HMNY announced that MoviePass had surpassed its 1 millionth subscriber!

Less than 30 days later, the stock spiked yet again as news broke that the company had grown to more than 1.5 million subscribers.

A couple of days later, more news broke. In an interview, the CEO of HMNY and the CEO of MoviePass were featured in an interview where they mentioned that not only will they consider getting into the blockchain space, but they have been considering it for more than a year now.




The Value Proposition Surrounding Helios And Matheson Analytics

At the end of the day, the big debate surrounding Helios and Matheson Analytics has to do with their value proposition. The idea here is that MoviePass is going to send the company to the top. However, there are some inherent issues here. MoviePass costs subscribers just $9.95 per month and gives them the ability to go to the movie theater whenever they’d like. The problem is that MoviePass is paying the full cost of a movie ticket every time subscribers use their passes.

Nonetheless, while the nay sayers have pointed a finger at the idea that MoviePass could generate a large loss if subscribers use it too much, HMNY argues that they are not seeing the true value here. The true value of MoviePass according to the company is the value of marketing and data. Ultimately, the bulls argue that HMNY and MoviePass could revive the entire film industry. In fact, leading figures seem to be getting on board as they see true value in what MoviePass is doing.

What We’re Seeing From The Stock Today

While Helios and Matheson Analytics has released quite a bit of news as of late, and it has all been positive, the stock seems to be taking a bit of a break today. Unfortunately, it is trading downward. As is just about always the case, our partners at Trade Ideas were the first to alert us to the fall. Currently (1:02), HMNY is trading at $7.33 per share after a loss of $0.31 per share or 4.11% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on HMNY. In particular, we’re interested in following the story surrounding MoviePass and following the progress on turning the data acquired into profit through the service. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7812
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...